Lacticaseibacillus paracasei L21 and Its Postbiotics Ameliorate Ulcerative Colitis Through Gut Microbiota Modulation, Intestinal Barrier Restoration, and HIF1α/AhR-IL-22 Axis Activation: Combined In Vitro and In Vivo Evidence
Combined in vitro and in vivo analysis demonstrates that lacticaseibacillus paracasei improves ulcerative colitis, suggesting new therapeutic strategies.
Key Points
Lacticaseibacillus paracasei L21 improves ulcerative colitis symptoms by restoring the intestinal barrier and regulating gut microbiota.
In vitro studies indicate significant reductions in pro-inflammatory cytokines and improvements in tight junction protein expression.
In vivo interventions showed less weight loss and lesser disease activity in ulcerative colitis mice models, enhancing immune response.
These findings support using L. paracasei L21 in probiotic and postbiotic formulations to manage ulcerative colitis effectively.